Role of principal ionotropic and metabotropic receptors in visceral pain

Journal of Neurogastroenterology and Motility

Volumn 21, Issue 2, 2015, Pages 147-158

  Kannampalli, Pradeep ^a   Sengupta, Jyoti N ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Ligand gated ion channels; Receptors, metabotropic glutamate; Visceral pain

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; ADX 71943; AMPA RECEPTOR; BACLOFEN; CANNABINOID RECEPTOR; DILTIAZEM; GLUTAMATE RECEPTOR; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; METABOTROPIC RECEPTOR; ML 204; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OPIATE RECEPTOR; RN 1734; SEROTONIN RECEPTOR; TARANABANT; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST; VANILLOID RECEPTOR ANTAGONIST;

HUMAN; NONHUMAN; REVIEW; VISCERAL PAIN;

EID: 84928531528     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm15026     Document Type: Review

References (120)

1. Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004; 20(suppl 7):31-39.
2. Patrizi F, Freedman SD, Pascual-Leone A, Fregni F. Novel therapeutic approaches to the treatment of chronic abdominal visceral pain. Scientific World Journal 2006;6:472-490.
3. Collett B. Visceral pain: the importance of pain management services Br J Pain 2013;7:6-7.
4. Camilleri M, Williams DE. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics 2000;17:331-338.
5. Farmer AD, Aziz Q. Visceral pain hypersensitivity in functional gastrointestinal disorders. Br Med Bull 2009;91:123-136.
6. Docherty MJ, Jones RC 3rd, Wallace MS. Managing pain in inflammatory bowel disease. Gastroenterol Hepatol (NY) 2011;7: 592-601.
7. Konturek SJ, Pawlik WW, Dajani EZ. Brain-gut axis in gastrointestinal system: introductory remarks. J Physiol Pharmacol 2003; 54(suppl 4):3-7.
8. Farmer AD, Aziz Q. Gut pain & visceral hypersensitivity. Br J Pain 2013;7:39-47.
9. Al-Chaer ED, Kawasaki M, Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 2000;119:1276-1285.
10. Lin C, Al-Chaer ED. Long-term sensitization of primary afferents in adult rats exposed to neonatal colon pain. Brain Res 2003;971: 73-82.
11. Ren K, Anseloni V, Zou SP, et al. Characterization of basal and re-inflammation-associated long-term alteration in pain responsivity following short-lasting neonatal local inflammatory insult. Pain 2004;110:588-596.
12. Walker SM, Franck LS, Fitzgerald M, Myles J, Stocks J, Marlow N. Long-term impact of neonatal intensive care and surgery on somatosensory perception in children born extremely preterm. Pain 2009;141:79-87.
13. Hathway GJ, Koch S, Low L, Fitzgerald M. The changing balance of brainstem-spinal cord modulation of pain processing over the first weeks of rat postnatal life. J Physiol 2009;587(Pt 12):2927-2935.
14. Miranda A, Mickle A, Schmidt J, et al. Neonatal cystitis-induced colonic hypersensitivity in adult rats: a model of viscero-visceral convergence. Neurogastroenterol Motil 2011;23:683, e281.
15. Broderick DF. Neuroimaging in neuropsychiatry. Psychiatr Clin North Am 2005;28:549-566.
16. Akbar A, Walters JR, Ghosh S. Review article: visceral hypersensitivity in irritable bowel syndrome: molecular mechanisms and therapeutic agents. Aliment Pharmacol Ther 2009;30:423-435.
17. Wesselmann U, Baranowski AP, Börjesson M, et al. Emerging therapies and novel approaches to visceral pain. Drug Discov Today Ther Strateg 2009;6:89-95.
18. Davis MP. Drug management of visceral pain: concepts from basic research. Pain Res Treat 2012;2012:265605.
19. Cervero F. Visceral pain-Central sensitisation. Gut 2000;47(suppl 4):iv56-iv57; discussion iv58.
20. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 2000;283:1710-1714.
21. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008;24:479-496.
22. de Carvalho Rocha HA, Dantas BP, Rolim TL, Costa BA, de Medeiros AC. Main ion channels and receptors associated with visceral hypersensitivity in irritable bowel syndrome. Ann Gastroenterol 2014;27:200-206.
23. Chebib M, Johnston GA. GABA-activated ligand gated ion channels: Medicinal chemistry and molecular biology. J Med Chem 2000;43:1427-1447.
24. Bormann J. The 'ABC' of GABA receptors. Trends Pharmacol Sci 2000;21:16-19.
25. Johnston GA. GABAA receptor channel pharmacology. Curr Pharm Des 2005;11:1867-1885.
26. Gassmann M, Bettler B. Regulation of neuronal GABAB receptor functions by subunit composition. Nat Rev Neurosci 2012; 13:380-394.
27. Goudet C, Magnaghi V, Landry M, Nagy F, Gereau RW 4th, Pin JP. Metabotropic receptors for glutamate and GABA in pain. Brain Res Rev 2009;60:43-56.
28. Enna SJ, McCarson KE. The role of GABA in the mediation and perception of pain. Adv Pharmacol 2006;54:1-27.
29. Mirza NR, Munro G. The role of GABAA receptor subtypes as analgesic targets. Drug News Perspect 2010;23:351-360.
30. Munro G, Hansen RR, Mirza NR. GABAA receptor modulation: potential to deliver novel pain medicines? Eur J Pharmacol 2013;716:17-23.
31. Sengupta JN, Pochiraju S, Kannampalli P, et al. MicroRNA-mediated GABAAα-1 receptor subunit down-regulation in adult spinal cord following neonatal cystitis-induced chronic visceral pain in rats. Pain 2013;154:59-70.
32. Brink TS, Hellman KM, Lambert AM, Mason P. Raphe magnus neurons help protect reactions to visceral pain from interruption by cutaneous pain. J Neurophysiol 2006;96:3423-3432.
33. Partosoedarso ER, Young RL, Blackshaw LA. GABAB receptors on vagal afferent pathways: peripheral and central inhibition. Am J Physiol Gastrointest Liver Physiol 2001;280:G658-G668.
34. Smid SD, Young RL, Cooper NJ, Blackshaw LA. GABABR expressed on vagal afferent neurones inhibit gastric mechanosensitivity in ferret proximal stomach. Am J Physiol Gastrointest Liver Physiol 2001;281:G1494-G1501.
35. Saulino M. The use of intrathecal baclofen in pain management. Pain Manag 2012;2:603-608.
36. Bussières N, El Manira A. GABAB receptor activation inhibits Nand P/Q-type calcium channels in cultured lamprey sensory neurons. Brain Res 1999;847:175-185.
37. Filippov AK, Couve A, Pangalos MN, Walsh FS, Brown DA, Moss SJ. Heteromeric assembly of GABABR1 and GABABR2 receptor subunits inhibits Ca2+ current in sympathetic neurons. J Neurosci 2000;20:2867-2874.
38. Wang X, Lambert NA. GABAB receptors couple to potassium and calcium channels on identified lateral perforant pathway projection neurons. J Neurophysiol 2000;83:1073-1078.
39. Sengupta JN, Medda BK. Shaker R. Effect of GABAB receptor agonist on distension-sensitive pelvic nerve afferent fibers innervating rat colon. Am J Physiol Gastrointest Liver Physiol 2002;283: G1343-G1351.
40. Brusberg M, Ravnefjord A, Martinsson R, Larsson H, Martinez V, Lindström E. The GABAB receptor agonist, baclofen, and the positive allosteric modulator, CGP7930, inhibit visceral pain-related responses to colorectal distension in rats. Neuropharmacology 2009; 56:362-367.
41. Hara K, Saito Y, Kirihara Y, Yamada Y, Sakura S, Kosaka Y. The interaction of antinociceptive effects of morphine and GABA receptor agonists within the rat spinal cord. Anesth Analg 1999;89: 422-427.
42. Lindström E, Brusberg M, Ravnefjord A, et al. Oral baclofen reduces visceral pain-related pseudo-affective responses to colorectal distension in rats: relation between plasma exposure and efficacy. Scand J Gastroenterol 2011;46:652-662.
43. Birder LA, de Groat WC. Contribution of C-fiber afferent nerves and autonomic pathways in the urinary bladder to spinal c-fos expression induced by bladder irritation. Somatosens Mot Res 1998; 15:5-12.
44. Lu Y, Westlund KN. Effects of baclofen on colon inflammationinduced Fos, CGRP and SP expression in spinal cord and brainstem. Brain Res 2001;889:118-130.
45. Hara K, Saito Y, Kirihara Y, Sakura S. The interaction between gamma-aminobutyric acid agonists and diltiazem in visceral antinociception in rats. Anesth Analg 2004 ;98:1380-1384.
46. Ong J, Kerr DI. Clinical potential of GABAB receptor modulators. CNS Drug Rev 2005;11:317-334.
47. Kalinichev M, Palea S, Haddouk H, et al. ADX71441, a novel, potent and selective positive allosteric modulator of the GABAB receptor, shows efficacy in rodent models of overactive bladder. Br J Pharmacol 2014;171:995-1006.
48. Kalinichev M, Donovan-Rodriguez T, Girard F, et al. Evaluation of peripheral versus central effects of GABAB receptor activation using a novel, positive allosteric modulator of the GABAB receptor ADX71943, a pharmacological tool compound with a fully peripheral activity profile. Br J Pharmacol 2014;171:4941-4954.
49. Di Lio A, Benke D, Besson M, et al. HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Neuropharmacology 2011;60:626-632.
50. Paul J, Yévenes GE, Benke D, et al. Antihyperalgesia by α2-GABAA receptors occurs via a genuine spinal action and does not involve supraspinal sites. Neuropsychopharmacology 2014;39:477-487.
51. Sun Y, Olson R, Horning M, Armstrong N, Mayer M, Gouaux E. Mechanism of glutamate receptor desensitization. Nature 2002; 417:245-253.
52. Banerjee B, Medda BK, Zheng Y, et al. Alterations in N-methyl-D-aspartate receptor subunits in primary sensory neurons following acid-induced esophagitis in cats. Am J Physiol Gastrointest Liver Physiol 2009;296:G66-G77.
53. Traynelis SF, Wollmuth LP, McBain CJ, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010;62:405-496.
54. Michaelis EK. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog Neurobiol 1998;54:369-415.
55. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg 2003;97:1108-1116.
56. Mori H, Mishina M. Structure and function of the NMDA receptor channel. Neuropharmacology 1995;34:1219-37.
57. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994;107:271-293.
58. Randic M, Jiang MC, Rusin KI, Cerne R, Kolaj M. Interactions between excitatory amino acids and tachykinins and long-term changes of synaptic responses in the rat spinal dorsal horn. Regul Pept 1993;46:418-420.
59. McRoberts JA, Coutinho SV, Marvizón JC, et al. Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats. Gastroenterology 2001;120:1737-1748.
60. Da Silva LF, Walder RY, Davidson BL, Wilson SP, Sluka KA. Changes in expression of NMDA-NR1 receptor subunits in the rostral ventromedial medulla modulate pain behaviors. Pain 2010; 151:155-161.
61. Miranda A, Mickle A, Bruckert M, Kannampalli P, Banerjee B, Sengupta JN. NMDA receptor mediates chronic visceral pain induced by neonatal noxious somatic stimulation. Eur J Pharmacol 2014;744:28-35.
62. Chen T, Wang W, Dong YL, et al. Postsynaptic insertion of AMPA receptor onto cortical pyramidal neurons in the anterior cingulate cortex after peripheral nerve injury. Mol Brain 2014;7:76-88.
63. Luo XQ, Cai QY, Chen Y, et al. Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord contributes to chronic visceral pain in rats. Brain Res 2014;1542:167-175.
64. Zhuo M. Long-term potentiation in the anterior cingulate cortex and chronic pain. Philos Trans R Soc Lond B Biol Sci 2013;369: 20130146.
65. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009;10:895-926.
66. Verne GN, Price DD, Callam CS, Zhang B, Peck J, Zhou Q. Viscerosomatic facilitation in a subset of IBS patients, an effect mediated by N-methyl-D-aspartate receptors. J Pain 2012;13: 901-909.
67. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999;51:7-61.
68. Xu H, Wu LJ, Zhao MG, et al. Presynaptic regulation of the inhibitory transmission by GluR5-containing kainate receptors in spinal substantia gelatinosa. Mol Pain 2006;2:29.
69. Jones CK, Alt A, Ogden AM, et al. Antiallodynic and antihyperalgesic effects of selective competitive GLUK5 (GluR5) ionotropic glutamate receptor antagonists in the capsaicin and carrageenan models in rats. J Pharmacol Exp Ther 2006;319:396-404.
70. Qiu CS, Lash-Van Wyhe L, Sasaki M, Sakai R, Swanson GT, Gereau RW 4th. Antinociceptive effects of MSVIII-19, a functional antagonist of the GluK1 kainate receptor. Pain 2011;152:1052-1060.
71. Zhang WG, Zhang LC, Peng ZD, Zeng YM. Intrathecal injection of GluR6 antisense oligodeoxynucleotides alleviates acute inflammatory pain of rectum in rats. Neurosci Bull 2009;25:319-323.
72. Cull-Candy S, Kelly L, Farrant M. Regulation of Ca2+-permeable AMPA receptors: synaptic plasticity and beyond. Curr Opin Neurobiol 2006;16:288-297.
73. Banerjee B, Medda BK, Pochiraju S, et al. AMPA receptor subunits expression and phosphorylation in cingulate cortex in rats following esophageal acid exposure. Neurogastroenterol Motil 2013; 25:973, e776.
74. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997;37:205-237.
75. Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 2010;50:295-322.
76. Salt TE, Jones HE, Copeland CS, Sillito AM. Function of mGlu1 receptors in the modulation of nociceptive processing in the thalamus. Neuropharmacology 2014;79:405-411.
77. Lindström E, Brusberg M, Hughes PA, et al. Involvement of metabotropic glutamate 5 receptor in visceral pain. Pain 2008;137:295-305.
78. Crock LW, Kolber BJ, Morgan CD, et al. Central amygdala metabotropic glutamate receptor 5 in the modulation of visceral pain. J Neurosci 2012;32:14217-14226.
79. Liu XH, Han M, Zhu JX, et al. Metabotropic glutamate subtype 7 and 8 receptors oppositely modulate cardiac nociception in the rat nucleus tractus solitarius. Neuroscience 2012;220:322-329.
80. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem 2004;73:953-990.
81. Ding YQ, Li JL, Lü BZ, Wang D, Zhang ML, Li JS. Co-localization of mu-opioid receptor-like immunoreactivity with substance P-LI, calcitonin gene-related peptide-LI and nitric oxide synthase-LI in vagal and glossopharyngeal afferent neurons of the rat. Brain Res 1998;792:149-153.
82. Aicher SA, Goldberg A, Sharma S, Pickel VM. μ-opioid receptors present in vagal afferents and their dendritic targets in the medial nucleus tractus solitaries. J Comp Neurol 2000;422:181-190.
83. Rau KK, Caudle RM, Cooper BY, Johnson RD. Diverse immunocytochemical expression of opioid receptors in electrophysiologically defined cells of rat dorsal root ganglia. J Chem Neuroanat 2005;29:255-264.
84. Su X, Sengupta JN, Gebhart GF. Effects of kappa opioid receptor-selective agonists on responses of pelvic nerve afferents to noxious colorectal distension. J Neurophysiol 1997;78:1003-1012.
85. Su X, Sengupta JN, Gebhart GF. Effects of opioids on mechanosensitive pelvic nerve afferent fibers innervating the urinary bladder of the rat. J Neurophysiol 1997;77:1566-1580.
86. Sengupta JN, Snider A, Su X, Gebhart GF. Effects of kappa opioids in the inflamed rat colon. Pain 1999;79:175-185.
87. Staahl C, Christrup LL, Andersen SD, Arendt-Nielsen L, Drewes AM. A comparative study of oxycodone and morphine in amulti-modal, tissue-differentiated experimental pain model. Pain 2006; 123:28-36.
88. Fichna J, Sibaev A, Salaga M, Sobczak M, Storr M. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice. Neurogastroenterol Motil 2013;25:e550-e559.
89. Sobczak M, Cami-Kobeci G, Salaga M, Husbands SM, Fichna J. Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastroin-testinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms. Eur J Pharmacol 2014;736:63-69.
90. Hughes PA, Castro J, Harrington AM, et al. Increased κ-opioid receptor expression and function during chronic visceral hypersensitivity. Gut 2014;63:1199-1200
91. Greenwood-van Meerveld B. Importance of 5-hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivity. Neurogastroenterol Motil 2007;19(suppl 2):13-18.
92. Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13(suppl 2):15-30.
93. Gershon MD. Review article: serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004;20(suppl 7):3-14.
94. Gershon MD, Tack J. The serotonin signalling system: From basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132:397-414.
95. Varnäs K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 2004;22:246-260.
96. Tonini M. 5-Hydroxytryptamine effects in the gut: the 3, 4 and 7 receptors. Neurogastroenterol Motil 2005;17:637-642.
97. Stasi C, Bellini M, Bassotti G, Blandizzi C, Milani S. Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Tech Coloproctol 2014;18:613-621.
98. Mickle A, Kannampalli P, Bruckert M, Miranda A, Banerjee B, Sengupta JN. Pronociceptive effect of 5-HT1A receptor agonist on visceral pain involves spinal N-methyl-D-aspartate (NMDA) receptor. Neuroscience 2012;219:243-254.
99. Sengupta JN, Mickle A, Kannampalli P, et al. Visceral analgesic effect of 5-HT4 receptor agonist in rats involves the rostroventral medulla (RVM). Neuropharmacology 2014;79:345-358.
100. Miranda A, Peles S, McLean PG, Sengupta JN. Effects of the 5-HT3 receptor antagonist, alosetron, in a rat model of somatic and visceral hyperalgesia. Pain 2006;126:54-63.
101. Storr MA, Yüce B, Andrews CN, Sharkey KA. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol Motil 2008;20:857-868.
102. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001;48:859-867.
103. Duncan M, Mouihate A, Mackie K, et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol 2008;295:G78-G87.
104. Feng CC, Yan XJ, Chen X, et al. Vagal anandamide signaling via cannabinoid receptor 1 contributes to luminal 5-HT modulation of visceral nociception in rats. Pain 2014;155:1591-1604.
105. Klooker TK, Leliefeld KE, Van Den Wijngaard RM, Boeckxstaens GE. The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients. Neurogastroenterol Motil 2011;23:30-35, e2.
106. Guo A, Vulchanova L, Wang J, Li X, Elde R. Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neliropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 1999;11:946-958.
107. Valtschanoff JG, Rustioni A, GuoA, Hwang SJ. Vanilloid receptor VR1 is both presynaptic and postsynaptic in the superficial laminae of the rat dorsal horn. J Comp Neurol 2001;436:225-235.
108. Hwang SJ, Valtschanoff JG. Vanilloid receptor VR1-positive afferents are distributed differently at different levels of the rat lumbar spinal cord. Neurosci Lett 2003;349:41-44.
109. Roberts LA, Connor M. TRPV1 antagonists as a potential treatment for hyperalgesia. Recent Pat CNS Drug Discov 2006;1:65-76.
110. MesseguerA, Planells-Cases R, Ferrer-Montiel A. Physiology and pharmacology of the vanilloid receptor. Curr Neuropharmacol 2006;4:1-15.
111. Lapointe TK, Altier C. The role of TRPA1 in visceral inflammation and pain. Channels 2011;5:525-529.
112. Matthews PJ, Aziz Q, Facer P, Davis JB, Thompson DJ, Anand P. Increased capsaicin receptor TRPV1 nerve fibers in the inflamed human oesophagus. Eur J Gastroenterol Hepatol 2004;16:897-902.
113. Adam B, Liebregts T, Gschossmann JM, et al. Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model. Pain 2006;123:179-186.
114. Akbar A, Yiangou Y, Facer P, et al. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut 2010;59:767-774.
115. Cattaruzza F, Spreadbury I, Miranda-Morales M, Grady EF, Vanner S, Bunnett NW. Transient receptor potential ankyrin-1 has a major role in mediating visceral pain in mice. Am J Physiol Gastrointest Liver Physiol 2010;298:G81-G91.
116. Charrua A, Cruz CD, Jansen D, Rozenberg B, Heesakkers J, Cruz F. Co-administration of transient receptor potential vanilloid 4 (TRPV4) and TRPV1 antagonists potentiate the effect of each drug in a rat model of cystitis. BJU Int 2015;115:452-460.
117. Jurik A, Ressle A, Schmid RM, Wotjak CT, Thoeringer CK. Supraspinal TRPV1 modulates the emotional expression of abdominal pain. Pain 2014;155:2153-2160.
118. Westlund KN, Zhang LP, Ma F, et al. A rat knockout model implicates TRPC4 in visceral pain sensation. Neuroscience 2014;262: 165-175.
119. Cervero F. Visceral pain: mechanisms of peripheral and central sensitization. Ann Med 1995;27:235-239.
120. Moshiree B, Zhou Q, Price DD, Verne GN. Central sensitisation in visceral pain disorders. Gut 2006;55:905-908.